Kim Helen Susan
CIK: 0001422772
Kim Helen Susan's purchase track record
Kim Helen Susan has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/12/2026 | AKTS | $15.03M | -20.3% | +17.6% | +7.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AKTS | ▼ Sell | Other | 4,859,370 | — | 1/12/2026 | View on chart |
| AKTS | ▲ Buy | Open Market | 812,455 | $14.6M | 1/12/2026 | View on chart |
| AKTS | ▼ Sell | Other | 134,842 | — | 1/12/2026 | View on chart |
| AKTS | ▲ Buy | Open Market | 22,545 | $406K | 1/12/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AKTS launches second Phase 1b trial for AKY-2519
Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.
AKTS launches second Phase 1b trial for AKY-2519. Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.